The development of multifunctional nanocarriers that leverage HSP70's tumour-specific overexpression while incorporating active transport mechanisms, such as receptor-mediated transcytosis, holds significant promise for enhancing therapeutic efficacy [237]. Here, HSPA1A is linked to neoplasm.